OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN ...
Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...
PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.
Among 459 participants, more with blood in urine saw it resolve on sefaxersen than placebo; blinded follow-up will measure ...
The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...
Share-transfer books are expected to close Nov. 5. Elme plans to move remaining assets to a trust; the trustee sets the ...
The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...
SUNS declared a prorated $0.09-per-share fourth-quarter dividend, payable Nov. 5 to holders of record Nov. 2; the merger ...
The 50-patient study reported 92% graft survival and 98% patient survival at one year; FDA assigned Dec. 19, 2026, as the ...
A greater share of patients with blood in urine at baseline saw it resolve on sefaxersen than placebo by week 37; kidney ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results